Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways, and enhanced target cell killing with alnuctamab, a B-cell maturation antigen targeting TCE.”
Title: Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways
Authors: Hsiling Chiu, Junfei Zhao, Tara Basavanhally, Chih-Chao Hsu, Michael D. Amatangelo, Gaurav Jain, Chad C. Bjorklund, Ting-Hsiang Huang, Lucia Y. Chen, Thomas A. Milne, Sarah Gooding, Samir Parekh, Anita Krithivas Gandhi, Maria Ortiz Estevez, Patrick Ryan Hagner
You can read the Full Article in Blood.
You can find other articles featuring Robert Orlowski on OncoDaily.
